Stereotactic Body Radiation Therapy as a Bridge to Transplantation and for Recurrent Disease in the Transplanted Liver of a Patient with Hepatocellular CarcinomaMazloom A.a · Hezel A.F.b · Katz A.W.a
aDepartment of Radiation Oncology, and bDivision of Hematology and Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, N.Y., USA Corresponding Author
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer mortality worldwide. Despite orthotopic liver transplantation (OLT), recurrent HCC is a major cause of morbidity. In this case report, we evaluate the efficacy of stereotactic body radiation therapy (SBRT) as a bridge to OLT and for recurrence in the transplanted liver of a patient with HCC. A 52-year-old male with a history of chronic hepatitis C presented with a 1.7-cm liver lesion radiographically consistent with HCC, which was subsequently treated with a course of SBRT to 50 Gy in 5 fractions followed by OLT in 2009. The patient had a 2.2-cm recurrence in the transplanted liver in 2012, which was treated with SBRT to 62.5 Gy in 5 fractions. He tolerated the course of radiotherapy well with no significant radiation-related toxicity and remains in complete remission approximately 1 year after SBRT. SBRT is a safe and effective modality for the treatment of recurrent HCC in the transplanted liver of the same patient initially treated with SBRT as a bridge to OLT.
© 2014 S. Karger AG, Basel
Hepatocellular carcinoma (HCC) is the third most common cause of cancer mortality worldwide and its incidence has been rising over the past 3 decades . Orthotopic liver transplantation (OLT) remains the preferred curative modality, providing a 70% five-year survival rate for patients meeting the Milan criteria . Despite adherence to the criteria, approximately 15% of patients will experience a recurrence in the transplanted liver .
In this case report, we describe a patient with HCC who was treated with stereotactic body radiation therapy (SBRT) as initial bridge therapy prior to transplant and for subsequent recurrence in the transplanted liver. Our Institutional Research Subject Review Board does not require informed consent from patients for a case report.
A 52-year-old male, undergoing surveillance because of long-standing hepatitis C, was found to have a rising α fetoprotein (AFP) level and a new 1.7-cm liver lesion consistent with HCC on a CT scan in October 2007. He was placed on the transplant list and underwent transarterial chemoembolization as bridging therapy in February 2008. The AFP level declined to normal, but within several months began to rise again. In August 2008, the patient was referred for SBRT.
The Novalis ExacTrac patient positioning platform (BrainLab AG, Heimstetten, Germany) was used for immobilization. Treatment planning was performed using the BrainScan system (BrainLab AG) and BrainLab treatment software. Treatment was prescribed to the 100% isodose line, with the 80% isodose line covering the planning target volume. Conformal arcs were used to deliver 50 Gy in ten 5 Gy daily fractions using 6-MV photons.
On May 10, 2009, the patient underwent an OLT. Pathologic examination of the native liver showed a 2.2-cm necrotic mass with no viable tumor identified. He did well following transplant until March 2011, when a rise in AFP up to 328 IU/ml was found.
A CT scan revealed an enlarged pericaval lymph node, which was biopsied and showed metastatic carcinoma. The lymph node was treated in May 2011 with SBRT to a dose of 50 Gy in 10 fractions. There was a good response to treatment based on repeat imaging studies as well as a significant decline in the AFP level.
However, in August 2012 there was a rapid rise in the patient's AFP level, reaching 1,590 IU/ml by October. In an October 2012 CT scan, a new 2.2-cm mass was seen in the left lobe of the liver and was treated with SBRT, 62.5 Gy in 5 fractions (fig. 1). At an initial follow-up after treatment, the lesion was stable on CT, and the AFP level had declined to 76 IU/ml. The most recent CT scan, almost 1 year after treatment, shows complete resolution of the treated lesion with no new suspicious disease. Follow-up examination also did not reveal any signs of liver disease or radiation-related toxicity (fig. 2).
|Fig. 1. SBRT plan for treatment of recurrent disease in the transplanted liver.|
|Fig. 2. CT scan 1 year after SBRT showing complete remission of the treated lesion.|
HCC is the most common malignancy of the liver, and the fifth most common malignancy in the world, with an annual incidence of 14.7 per 100,000 men and 4.9 per 100,000 women [4,5]. OLT is the preferred modality for treatment in patients with HCC, with a reported 5-year survival rate of 73% for patients meeting the Milan criteria for HCC . Upon adoption of the Milan criteria for liver transplantation, the incidence of HCC recurrence significantly decreased, while the survival rate improved from 25 to 61% . However, despite the significant improvement in survival rates of patients with HCC following OLT over the past 20 years, recurrent HCC continues to be a major cause of morbidity. Furthermore, the major site of relapse for patients who have undergone liver transplantation is the transplanted liver. The rate of relapse in the transplanted liver is 4-39% in the different series, perhaps reflecting clinical differences of patients referred for liver transplantation [3,7,8,9]. The treatment of posttransplant patients can be challenging due to the concurrent requirement for immunosuppressive medication, and the difficulties and risks of using other locoregional therapies such as ablation or chemoembolization.
SBRT enables the precise delivery of a high dose of radiation to the tumor in a limited number of fractions. This allows for a higher biologically effective dose so that the HCC is ablated without a significant increase in liver toxicity, allowing for a higher therapeutic ratio . Previous studies have shown the safety and efficacy of SBRT in tumor control in the native liver with an in-field control rate of 68-98% [10,11].
In this report, we describe the successful treatment of recurrent HCC in a transplanted liver with SBRT. Our patient tolerated his course of radiotherapy well with no significant acute or late toxicity despite having received SBRT prior to transplant. Though tumor recurrence in the transplanted liver continues to be a significant cause of morbidity for patients with HCC, on follow-up, our patient continues to be in complete remission with no significant signs of radiation-related toxicity. We believe that SBRT is a safe and effective modality for the treatment of recurrent HCC following liver transplantation.
The authors thank Ms. Laura Finger for editorial assistance.
The authors declare no conflicts of interest.
Ali Mazloom, MD
Department of Radiation Oncology, University of Rochester Medical Center
601 Elmwood Avenue, Box 647
Rochester, NY 14642 (USA)
Published online: January 10, 2014
Number of Print Pages : 5
Number of Figures : 2, Number of Tables : 0, Number of References : 11
Case Reports in Oncology
Vol. 7, No. 1, Year 2014 (Cover Date: January-April)
Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 1662-6575 (Print), eISSN: 1662-6575 (Online)
For additional information: http://www.karger.com/CRO